MX2023005455A - Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. - Google Patents
Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.Info
- Publication number
- MX2023005455A MX2023005455A MX2023005455A MX2023005455A MX2023005455A MX 2023005455 A MX2023005455 A MX 2023005455A MX 2023005455 A MX2023005455 A MX 2023005455A MX 2023005455 A MX2023005455 A MX 2023005455A MX 2023005455 A MX2023005455 A MX 2023005455A
- Authority
- MX
- Mexico
- Prior art keywords
- administering
- methods
- heart failure
- treating heart
- omecamtiv mecarbil
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- RFUBTTPMWSKEIW-UHFFFAOYSA-N omecamtiv mecarbil Chemical compound C1CN(C(=O)OC)CCN1CC1=CC=CC(NC(=O)NC=2C=NC(C)=CC=2)=C1F RFUBTTPMWSKEIW-UHFFFAOYSA-N 0.000 title abstract 2
- 229950001617 omecamtiv mecarbil Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En el presente documento se proporcionan métodos de tratamiento de la insuficiencia cardíaca en pacientes que presenten uno o más elementos adicionales, que comprenden administrar al paciente una cantidad con eficacia terapéutica de omecamtiv mecarbil, o un hidrato, una sal o una sal de un hidrato de este.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112995P | 2020-11-12 | 2020-11-12 | |
| US202163154077P | 2021-02-26 | 2021-02-26 | |
| US202163187084P | 2021-05-11 | 2021-05-11 | |
| US202163202873P | 2021-06-28 | 2021-06-28 | |
| US202163203436P | 2021-07-22 | 2021-07-22 | |
| PCT/US2021/058988 WO2022103966A1 (en) | 2020-11-12 | 2021-11-11 | Methods of treating heart failure by administering omecamtiv mecarbil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005455A true MX2023005455A (es) | 2023-07-27 |
Family
ID=78822539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005455A MX2023005455A (es) | 2020-11-12 | 2021-11-11 | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12194039B2 (es) |
| EP (1) | EP4243825A1 (es) |
| JP (1) | JP2024500616A (es) |
| KR (1) | KR20230107282A (es) |
| AU (1) | AU2021380754A1 (es) |
| CA (1) | CA3200673A1 (es) |
| CL (2) | CL2023001351A1 (es) |
| IL (1) | IL302850A (es) |
| MX (1) | MX2023005455A (es) |
| TW (1) | TW202233189A (es) |
| WO (1) | WO2022103966A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006009726A2 (en) | 2004-06-17 | 2006-01-26 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| MA44637B1 (fr) | 2013-03-14 | 2021-04-30 | Amgen Inc | Composes hétérocycliques et leurs utilisations |
| PH12019502883A1 (en) | 2017-06-30 | 2020-10-26 | Amgen Inc | Synthesis of omecamtiv mecarbil |
| JP2020526483A (ja) | 2017-06-30 | 2020-08-31 | アムジエン・インコーポレーテツド | 心筋節活性化剤で心不全を治療する方法 |
| ES2815899T3 (es) | 2018-07-09 | 2021-03-31 | Fis Fabbrica Italiana Sintetici Spa | 2-Fluoro-3-nitrotolueno cristalino y procedimiento para la preparación del mismo |
| MA53226A (fr) | 2018-08-17 | 2021-11-24 | Amgen Inc | Sel et formes cristallines d'omecamtiv mecarbil |
| KR20230107282A (ko) | 2020-11-12 | 2023-07-14 | 암젠 인크 | 오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법 |
| KR20240006498A (ko) | 2021-03-10 | 2024-01-15 | 암젠 인크 | 오메캄티브 메카빌의 합성 |
| US20250161298A1 (en) * | 2022-02-22 | 2025-05-22 | Yale University | Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth |
| WO2024081611A1 (en) * | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| US6303144B1 (en) | 1998-02-10 | 2001-10-16 | Welfide Corporation | Preparations with controlled release |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| WO2004033036A2 (en) | 2002-10-04 | 2004-04-22 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
| WO2006009726A2 (en) | 2004-06-17 | 2006-01-26 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| EP1959960B1 (en) | 2005-12-15 | 2013-04-10 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| EP2020989A2 (en) | 2006-05-15 | 2009-02-11 | Wisconsin Allumni Research Foundation | Pulmonary delivery of 1,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin |
| FR2902092B1 (fr) | 2006-06-07 | 2008-09-05 | Sapelem Soc Par Actions Simpli | Appareil de manutention de charge |
| JP5302952B2 (ja) | 2007-04-19 | 2013-10-02 | ドン・ア・ファーム・カンパニー・リミテッド | 糖調節ペプチドの制御放出に適した生分解性マイクロスフェア組成物及びその製造方法 |
| MA44637B1 (fr) | 2013-03-14 | 2021-04-30 | Amgen Inc | Composes hétérocycliques et leurs utilisations |
| JP6634368B2 (ja) | 2013-03-14 | 2020-01-22 | アムジエン・インコーポレーテツド | 複素環式化合物及びそれらの使用 |
| CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| CA2988796A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
| CA3052625A1 (en) | 2017-02-06 | 2018-08-09 | Acceleron Pharma Inc. | Compositions and methods for treating heart failure |
| PH12019502883A1 (en) | 2017-06-30 | 2020-10-26 | Amgen Inc | Synthesis of omecamtiv mecarbil |
| JP2020526483A (ja) | 2017-06-30 | 2020-08-31 | アムジエン・インコーポレーテツド | 心筋節活性化剤で心不全を治療する方法 |
| ES2815899T3 (es) | 2018-07-09 | 2021-03-31 | Fis Fabbrica Italiana Sintetici Spa | 2-Fluoro-3-nitrotolueno cristalino y procedimiento para la preparación del mismo |
| WO2020014406A1 (en) | 2018-07-12 | 2020-01-16 | Assia Chemical Industries Ltd. | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
| FI3599243T3 (fi) | 2018-07-26 | 2023-06-22 | Cvie Therapeutics Ltd | 17beeta-heterosyklyylidigitaliksen kaltaisia yhdisteitä sydämen vajaatoiminnan hoitoon |
| MA53226A (fr) | 2018-08-17 | 2021-11-24 | Amgen Inc | Sel et formes cristallines d'omecamtiv mecarbil |
| US20220042055A1 (en) | 2018-12-18 | 2022-02-10 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| BR112021017009A2 (pt) | 2019-03-05 | 2021-11-09 | Windtree Therapeutics Inc | Formulação intravenosa contendo istaroxima para o tratamento da insuficiência cardíaca aguda (ahf) |
| EP4031541A1 (en) | 2019-09-19 | 2022-07-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| US20220348543A1 (en) | 2019-09-19 | 2022-11-03 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| EP4041710A1 (en) | 2019-10-09 | 2022-08-17 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
| WO2021070123A1 (en) | 2019-10-09 | 2021-04-15 | Dr. Reddy’S Laboratories Limited | Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof |
| MX2022005465A (es) | 2019-11-10 | 2022-08-08 | Myokardia Inc | Metodos de tratamiento con modulador de miosina. |
| GB201918853D0 (en) | 2019-12-19 | 2020-02-05 | Lund Lars H | Methods of treatment |
| WO2021136477A1 (zh) | 2020-01-03 | 2021-07-08 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
| EP4103159A1 (en) | 2020-02-10 | 2022-12-21 | Amgen Inc. | Omecamtiv mecarbil tablet |
| KR20230107282A (ko) | 2020-11-12 | 2023-07-14 | 암젠 인크 | 오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법 |
| KR20240006498A (ko) | 2021-03-10 | 2024-01-15 | 암젠 인크 | 오메캄티브 메카빌의 합성 |
| WO2023205291A2 (en) | 2022-04-21 | 2023-10-26 | The Board Of Regents Of The University Of Oklahoma | Targeting myocardial tissue for delivery of therapeutic and imaging agents |
| WO2024081611A1 (en) | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
-
2021
- 2021-11-11 KR KR1020237019053A patent/KR20230107282A/ko active Pending
- 2021-11-11 AU AU2021380754A patent/AU2021380754A1/en active Pending
- 2021-11-11 JP JP2023528276A patent/JP2024500616A/ja active Pending
- 2021-11-11 MX MX2023005455A patent/MX2023005455A/es unknown
- 2021-11-11 IL IL302850A patent/IL302850A/en unknown
- 2021-11-11 EP EP21820408.9A patent/EP4243825A1/en active Pending
- 2021-11-11 CA CA3200673A patent/CA3200673A1/en active Pending
- 2021-11-11 WO PCT/US2021/058988 patent/WO2022103966A1/en active Application Filing
- 2021-11-11 US US17/454,592 patent/US12194039B2/en active Active
- 2021-11-11 TW TW110142070A patent/TW202233189A/zh unknown
-
2023
- 2023-05-10 CL CL2023001351A patent/CL2023001351A1/es unknown
-
2024
- 2024-02-15 CL CL2024000466A patent/CL2024000466A1/es unknown
- 2024-12-03 US US18/967,331 patent/US20250205228A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022103966A9 (en) | 2022-08-18 |
| KR20230107282A (ko) | 2023-07-14 |
| WO2022103966A1 (en) | 2022-05-19 |
| CA3200673A1 (en) | 2022-05-19 |
| AU2021380754A1 (en) | 2023-06-22 |
| EP4243825A1 (en) | 2023-09-20 |
| AU2021380754A9 (en) | 2024-10-24 |
| JP2024500616A (ja) | 2024-01-10 |
| CL2023001351A1 (es) | 2023-10-20 |
| CL2024000466A1 (es) | 2024-08-30 |
| TW202233189A (zh) | 2022-09-01 |
| US20220184068A1 (en) | 2022-06-16 |
| US20250205228A1 (en) | 2025-06-26 |
| IL302850A (en) | 2023-07-01 |
| US12194039B2 (en) | 2025-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005455A (es) | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. | |
| MX2022004137A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| PH12020551597A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| CY1116925T1 (el) | Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια | |
| BR112022002609A2 (pt) | Métodos de tratamento de tumores estromais gastrointestinais | |
| MX2020006284A (es) | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| MX2024011142A (es) | Tratamiento de neurofibromas cutaneos con mirdametinib. | |
| PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
| EA202090558A1 (ru) | Схемы лечения | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| EA202193211A1 (ru) | Лечение синуклеопатий | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| EP4327869A3 (en) | Methods of treating fabry patients having renal impairment | |
| PL1732551T3 (pl) | Perheksylina do leczenia przewlekłej niewydolności serca | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| PH12022550721A1 (en) | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |